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OATP1B1 and tumour OATP1B3 modulate
exposure, toxicity, and survival after
irinotecan-based chemotherapy
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N6A 5W9; 3Department of Pathology, London Health Sciences Centre – University Hospital, Western University, 339 Windermere
Road, London, Ontario, Canada N6A 5A5; 4Department of Epidemiology and Biostatistics, Kresge Building, Western University,
London Ontario, Canada N6A 5C1 and 5Department of Physiology and Pharmacology, Medical Sciences Building, Western
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Background: Treatment of advanced and metastatic colorectal cancer with irinotecan is hampered by severe toxicities. The active
metabolite of irinotecan, SN-38, is a known substrate of drug-metabolising enzymes, including UGT1A1, as well as OATP and ABC
drug transporters.
Methods: Blood samples (n ¼ 127) and tumour tissue (n ¼ 30) were obtained from advanced cancer patients treated with
irinotecan-based regimens for pharmacogenetic and drug level analysis and transporter expression. Clinical variables, toxicity, and
outcomes data were collected.
Results: SLCO1B1 521C was significantly associated with increased SN-38 exposure (Po0.001), which was additive with
UGT1A1*28. ABCC5 (rs562) carriers had significantly reduced SN-38 glucuronide and APC metabolite levels. Reduced risk of
neutropenia and diarrhoea was associated with ABCC2–24C/T (odds ratio (OR) ¼ 0.22, 0.06–0.85) and CES1 (rs2244613; OR ¼ 0.29,
0.09–0.89), respectively. Progression-free survival (PFS) was significantly longer in SLCO1B1 388G/G patients and reduced in
ABCC2–24T/T and UGT1A1*28 carriers. Notably, higher OATP1B3 tumour expression was associated with reduced PFS.
Conclusions: Clarifying the association of host genetic variation in OATP and ABC transporters to SN-38 exposure, toxicity and
PFS provides rationale for personalising irinotecan-based chemotherapy. Our findings suggest that OATP polymorphisms and
expression in tumour tissue may serve as important new biomarkers.

Irinotecan (CPT-11) is currently approved for the treatment of
advanced or metastatic colorectal cancer as a single agent or in
combination chemotherapy regimens (Paulik et al, 2012; BekaiiSaab and Wu, 2014). CPT-11 is a semi-synthetic camptothecin
analogue capable of blocking DNA replication and transcription
through topoisomerase-I inhibition (Marsh and Hoskins, 2010).
This prodrug has a complex metabolic pathway where the first
step is rapid bioactivation to its active metabolite SN-38, by

carboxylesterases (CES1 and CES2) expressed in the liver, as well
as to a lesser extent in plasma, gastrointestinal (GI) tract, and
tumour tissue (Paulik et al, 2012). SN-38 is subsequently detoxified
by uridine disphosphate glucuronosyltransferases (UGTs), mainly
UGT1A1, to form the inactive metabolite SN-38 glucuronide (SN38G). CPT-11 also undergoes CYP3A4/5-dependent oxidation to
form the inactive metabolites M4, APC, and NPC with the latter
available for further conversion to SN-38 (Kweekel et al, 2008).
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Increased systemic exposure to SN-38 places patients at an elevated
risk of developing severe neutropenia as well as diarrhoea, which is
thought to involve reconversion of SN-38G to SN-38 via intestinal
b-glucuronidases (Paulik et al, 2012). Currently, although UGT1A1
polymorphisms are considered important, pharmacogenomic variables are not routinely considered when prescribing CPT-11, and
dosing tends to be based on body surface area, clinical variables, and
history or onset of adverse events (Kweekel et al, 2008).
The majority of CPT-11 pharmacogenetic studies have focused
on the role of UGT1A1. Elevation in the level of SN-38, among
patients with UGT1A1*28 polymorphism, has been linked to severe
CPT-11-induced toxicities including neutropenia and diarrhoea
(Innocenti et al, 2009; Sai et al, 2010). Results from a meta-analysis
suggest the risk of severe haematological toxicities in homozygous
UGT1A1*28 patients is dose dependent with those receiving high
doses (4250 mg m  2) at the greatest risk. Although variant
patients receiving intermediate doses (150–250 mg m  2) of
CPT-11 are at significantly increased risks compared with patients
with at least one wild-type allele, the odds of toxicity may be within
an acceptable range if no other risk factors for neutropenia are
present (Hoskins et al, 2007), questioning the usefulness of
genotyping patients prescribed low-to-intermediate doses of
CPT-11 before administration. Although it appears UGT1A1 has
an important role in the development of CPT-11-related adverse
events in some patients, there are many lacking known UGT
polymorphisms who suffer from dose-limiting toxicities during
CPT-11 therapy. Indeed, the interplay of numerous genes in the
CPT-11 metabolism and disposition pathways is likely the basis for
often unpredictably severe toxicity during CPT-11 therapy.
There is an increasing appreciation of the role of drug uptake
and efflux transporters, both in organs such as the intestine and
liver, as well in tumour, to the disposition and response to drugs in
clinic use. We know that uptake transporters, such as OATP1B1
(SLCO1B1) are required for hepatic influx of SN-38, whereas ABC
transporters including ABCC1, ABCC2, ABCB1, and ABCG2
regulate the hepatic and biliary efflux of CPT-11 metabolites
(Fujiwara and Minami, 2010). Polymorphisms within SLCO1B1,
ABCB1, and ABCC2 have recently been associated with modulation
of CPT-11 and SN-38 exposure (Innocenti et al, 2009; Sai et al,
2010). Additional polymorphisms in ABCG2 and ABCC5 have
recently been correlated with non-haematological toxicities
(Di Martino et al, 2011; De Mattia et al, 2013). However,
pharmacogenetic studies have demonstrated mixed results regarding
the role of drug transporters to adverse events and response
(Mathijssen and Gurney, 2009; Fujiwara and Minami, 2010). CPT-11
dose and schedule as well as ethnic differences in the populations
studied provide plausible explanations for the wide variation in
results.
The complexity of predicting response to CPT-11 therapy may
be further hampered by the lack of ability to assess active drug
concentrations within tumour tissue. Influx of SN-38 to the
tumour may be dependent on the SN-38 uptake transporter
OATP1B3 (SLCO1B3), which our group and others had shown to
be highly upregulated in various cancer tissues including colon
(Lee et al, 2008; Yamaguchi et al, 2008; Obaidat et al, 2012; Fujita
et al, 2014). Recently, a cancer-specific isoform of OATP1B3
(csOATP1B3), lacking the first 28 amino acids in colon cancer
tissues, has been identified (Nagai et al, 2012; Thakkar et al, 2013).
Expression of csOATP1B3 appears to be induced under hypoxic
conditions that are often associated with advanced solid cancers
and poorer clinical outcomes (Han et al, 2013). It remains
unknown if csOATP1B3 expression is predictive of response to
CPT-11 therapy.
Determining the overall contribution of genetic variation in
drug transporters as well as metabolising enzymes will be essential
to tailoring CPT-11 doses for individual patients. In this study, our
primary objective was to better correlate the effects of genetic
858
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variation in drug transporters, as well as enzymes such as
UGT1A1, with measured CPT-11 and metabolite levels among
cancer patients receiving irinotecan-based chemotherapy regimens
in a prospective manner. Our secondary objective was to assess the
impact of pharmacogenetic factors to the development of adverse
events and progression-free survival (PFS). Finally, tumour tissues
obtained from a cohort of these patients were analysed for
OATP1B3 expression and its effect on PFS.
MATERIALS AND METHODS

Study population. Metastatic colorectal cancer and advanced or
metastatic pancreatic cancer patients (n ¼ 127) being treated with
CPT-11-based chemotherapy regimens were prospectively
recruited between January 2010 and November 2012 from the
London Regional Cancer Program, London Health Sciences
Centre, London, Ontario, Canada. The majority of patients were
prescribed CPT-11 at 180 mg m  2 biweekly in combination with
5-fluorouracil and leucovorin (FOLFIRI regimen) with or without
bevacuzimab. Patients were included if they were aged 18 years or
above with an ECOG (Eastern Cooperative Oncology Group)
performance status p2. Exclusion criteria included: 435 mmol l  1
total bilirubin, 43X upper normal limit AST or ALT without liver
metastases or 45X with liver metastases, known hypersensitivity
to CPT-11, known history of Gilbert’s syndrome, and concurrent
use of ketoconazole. All participants provided written informed
consent. The study was approved by the Research Ethics Board at
Western University.
Chart review. Paper and electronic record chart review for each
consented patient was conducted by a single reviewer. Age
recorded was the age at initiation of CPT-11-based chemotherapy.
A cycle of CPT-11 was defined as a single administration of
CPT-11 alone or in combination, irrespective of the chemotherapy
regimen used. Treatment-related toxicities were recorded for the
cycle where the blood sample was obtained in addition to any
toxicities occurring throughout the duration of treatment with
CPT-11. The blood sample cycle was considered to extend to the
subsequent measurement of basic laboratory values and/or clinical
assessment. Toxicities during this period were not considered to be
associated with the particular treatment if they were documented
more than 3 weeks after sample blood drawn. NCI-CTCAE version
3.0 (Bethesda, MD, USA) was used to grade toxicities. Toxicity
grade was determined using subjective measures (described in
clinical notes) when exact grading was not documented.
Responders were defined as having a stable or reduced tumour
size on the first CT scan following CPT-11-based chemotherapy
initiation. The interval between CT scans was at the discretion of
the treating oncologist. Progression was defined as the date the CT
or MRI reported an increased tumour size. Progression-free
survival was considered to be the time from initiation of CPT11-based chemotherapy to the date of progression, death, last
contact, or censor date (13 August 2013), whichever occurred first.
Genotyping. DNA was extracted from whole blood using the
Gentra Purgene Blood Kit (Qiagen, Toronto, Ontario, Canada).
The following TaqMan allelic discrimination assays (Applied
Biosystems, Carlsbad, CA, USA) were used for genotyping:
ABCB1 (c.3435C4T, rs1045642), ABCG2 (c.421C4A, rs2231142;
c.34G4A, rs2231137), ABCC2 (c.-24C4T, rs717620; c.1249G4A,
rs2273697), ABCC5 (T4C, rs562), SLCO1B1*1b (c.388A4G,
rs2306283), SLCO1B1*5 (c.521T4C, rs4149056), SLCO1B3
(g.699G4A, rs7311358), UGT1A1*28 (TA(6/7), rs8175347), CES1
(g.14506G4A, rs71647871; g.27467A4C, rs2244613), CYP3A4*22
(intron 6 C4T, rs35599367), and CYP3A5*3 (g.6986A4G,
rs776746). Hardy–Weinburg equilibrium was assessed for all
genotypes using the w2 goodness-of-fit test.
www.bjcancer.com | DOI:10.1038/bjc.2015.5
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Drug levels. Blood samples were obtained by venipuncture of the
opposite arm immediately following the end of the CPT-11
infusion (90 min) during any cycle of CPT-11-based chemotherapy. Plasma was collected and stored at  80 1C until analysis.
Plasma concentrations of CPT-11 and metabolites SN-38, SN-38G,
and APC (7-ethyl-10-[4-N-(5-aminopentanoic acid)-1-piperidino]
carbonyloxycamptothecin) were measured by liquid chromatography-tandem mass spectrometry. Standards were obtained from
Sigma-Aldrich (Oakville, Ontario, Canada; CPT-11, SN-38) and
Toronto Research Chemicals (Toronto, Ontario, Canada; SN-38glucuronide, APC). Plasma samples (100 ml) were precipitated
upon addition of 3 volumes of acetonitrile and 0.1% formic acid
(FA) spiked with 15 ml internal standard (camptothecin,
500 ng ml  1, Toronto Research Chemicals). Samples were
vortexed, centrifuged, and diluted with H2O (0.1% FA). Analytes
were injected (30 ml) into the liquid chromatograph (Agilent 1200)
and separated on a reverse-phase column (Hypersil Gold,
50  5 mm, 5 mM particle size) over 6 min using gradient elution
with H2O (0.1% FA) and acetonitrile (0.1% FA) (10–90%).
Standard curves and quality controls (co-efficient of variation
(%), high (13.5), med (2.6), low (3.7)) were prepared in
drug-free plasma. The mass spectrometer (Thermo TSQ Vantage,
Burlington, ON, Canada) with heated electrospray ionisation
source was set in positive mode for detection of CPT-11, SN-38,
SN-38G, APC, and camptothecin with transitions 587-124 m/z,
393-349.3 m/z, 569-393.3 m/z, 691-227 m/z, 349-305 m/z,
respectively.
Immunohistochemistry. Archived normal and tumour tissue
biopsy slides were obtained from a subset of study participants
(n ¼ 30) following approval by the Tissue and Archive Committee
(Department of Pathology, London Health Sciences Centre).
Antigen retrieval was performed with citrate buffer and slides
were subsequently incubated with pre-immune serum or
anti-OATP1B3 polyclonal antibody (1 : 200) followed by an
avidin-biotin immunoperoxidase assay and developed using an
AEC (3-Amino-9-ethylcarbazole) staining kit (Sigma-Aldrich)
using a modified protocol (Lee et al, 2008). Nuclei were counterstained using Mayer’s haematoxylin (Sigma-Aldrich). Scoring for
OATP1B3 expression in normal, normal adjacent, and tumour
tissue was performed independently by one pathologist (JP).
Staining intensity for OATP1B3 was defined and evaluated using
the following semi-quantitative previously published method:
(0) no staining, (1) weakly positive, (2) moderately positive, and
(3) strongly positive (Lee et al, 2008).
Statistics. The primary objective was to determine covariates
associated with interindividual variability of CPT-11 and metabolite plasma concentration. All statistical analysis was performed in
GraphPad Prism and the statistical software R. One-way analysis of
variance with Bonferroni correction and Student’s t-tests was used
to compare drug levels between genotypic groups. Multiple linear
regression analysis was performed to determine significant
covariates on the interindividual variability of dose-normalised
CPT-11 and metabolite plasma concentrations (natural logtransformed). Covariates considered included: age, sex, treatment
regimen, ABCB1, ABCG2, ABCC2, ABCC5, SLCO1B1, SLCO1B3,
UGT1A1, CES1, CYP3A4, and CYP3A5 genotype. Covariates were
assessed individually and were considered for the final model at a
significance level of Po0.2. Covariates meeting these criteria were
entered into a multiple linear regression model adjusting for age,
sex, and treatment regimen and remained in the final model if
Po0.1.
Secondary outcomes included assessing covariates associated
with toxicity and PFS. Multinomial logistic regression analysis was
used to determine association of genotype with toxicity events
after adjustment for sex, age, and treatment regimen. Toxicity
categories used in the regression analysis were: neutropenia
www.bjcancer.com | DOI:10.1038/bjc.2015.5
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(no event vs low (grade 1 or 2) vs high (grade 3 or 4)) and
diarrhoea, nausea/vomiting and oral mucositis (no event vs low
(grade 1) vs high (grade 2 or 3)). Univariate analysis was performed
for each covariate and only significant genotypes were included in
the final model with the exception of adjustment covariates as
indicated above. Logistic regression analysis was also performed to
determine covariates associated with neutropenia (low (grade 0, 1
or 2) vs high (grade 3 or 4)). Cox regression analysis was used to
determine association of covariates with PFS in patients treated
with BEV-FOLFIRI or FOLFIRI regimens (excluding patients
with pancreatic cancer). Univariate analysis was performed and
covariates with a cut value of Po0.2 were included in the final
multivariate analysis with the exception of adjusting covariates, age
at enrolment, sex and treatment regimen. Kruskal–Wallis with
Dunn’s multiple comparative test and Wilcoxon signed rank test
was used to compare OATP1B3 pathology scores. Mann–Whitney
U-test was used to compare OATP1B3 pathology scores and PFS in
patients treated with CPT-11-based chemotherapy regimens scored
for OATP1B3 tumour expression (0–1 vs 2–3).
RESULTS

Study population. Patient and tumour characteristics (n ¼ 127) are
described in Table 1. The treatment profile of patients is presented in
Table 2. Approximately half (55%) of the study population had not
received previous chemotherapy and the majority of patients (82%)
were treated with bevacizumab (BEV)-FOLFIRI or FOLFIRI
chemotherapy regimens as first-line therapy (Table 2).
OATP1B1 and ABCC5 are important determinants of SN-38
and SN-38G levels. The primary objective was to determine
Table 1. Patient and tumour characteristics (n ¼ 127)
Variable

n (%)

Demographics
Male
Median age; range (years)
Ethnicity (Caucasian)

86 (67.7)
61; 27–83
119 (93.7)

ECOG status
0
1
2

61 (48.0)
50 (39.4)
2 (1.6)

Tumour histology
Colon
Rectal
Pancreatic
Othera

62
45
13
7

(48.8)
(35.4)
(10.2)
(5.5)

Tumour grade
Grade 1
Grade 2
Grade 3

84 (65.6)
25 (19.5)
13 (10.2)

Number of metastases
p2
3–4
44

24 (18.8)
22 (17.2)
80 (62.5)

Location of metastases
Liver
Lung
Peritoneum
Bone
Brain
Other

95
51
37
16
4
11

(74.2)
(39.8)
(28.9)
(12.5)
(3.1)
(8.6)

Abbreviation: ECOG=Eastern Cooperative Oncology Group.
a
Includes unknown primary, appendiceal carcinoid, neuroendocrine, gall bladder, signet
ring cell.
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covariates associated with interindividual variability of plasma
concentrations of CPT-11 and metabolites. Plasma concentrations
of CPT-11, SN-38, SN-38G, and APC were measured from blood
samples collected immediately following the end of CPT-11

Table 2. Treatment profile (n ¼ 127)
Variable

n (%)

Previous chemotherapy
No
One line
Two or more lines

70 (55.1)
40 (31.5)
17 (13.4)

Irinotecan-based chemotherapy administered
Bevacizumab-FOLFIRI
FOLFIRI
FOLFIRINOX
Irinotecan

85
19
14
8

(66.9)
(15.0)
(11.0)
(6.3)

Further treatment provided
Chemotherapy
Surgical metastectomy

66 (52.5)
13 (10.2)

No. of prior cycles of irinotecan
0–1
2–4
X5

34 (27.6)
41 (33.3)
48 (39.0)

Dose reduction at sample draw
No. of reduction
p20%
420%

77 (60.6)
29 (22.9)
21 (16.5)

Outcomes
Responder
Median PFS; range (months)

93 (73.2)
10.5 (0.2—43.0)

Abbreviations: FOLFIRI ¼ 5-fluorouracil, irinotecan, leucovorin; FOLFIRINOX ¼ 5-fluorouracil, irinotecan, leucovorin, oxaliplatin; PFS ¼ progression-free survival.

4
CSN-38 / dose / BSA
(10 –4 m2 ml–1)

*
100

50

3
2
1

0
C/ T

T/ T

T/ T

ABCB1 3435C>T

3

*

**

2
1
0

0
C/C

4

***
CSN-38 / dose / BSA
(10 –4 m2 ml–1)

150
CCPT-11 / dose / BSA
(10 –4 m2 ml–1)

infusion. Multiple linear regression was performed on dosenormalised drug levels (natural log transformed) adjusting for age
at time of treatment initiation, sex and treatment regimen in the
final models. ABCB1 (c.3435 C4T) was significantly associated
with CPT-11 exposure as homozygous variant (T/T) carriers had
lower levels compared with wild-type patients (Po0.05; Figure 1A
and Supplementary Table 1). This model had one significant
adjusting covariate (FOLFIRI treatment regimen, P o0.05).
Several genotypes were significantly associated with variation in
SN-38 levels as part of a model that explained approximately 27%
of the variation in exposure (Table 3). SLCO1B1 521C allele
carriers had significantly increased systemic exposure to SN-38
(Po0.001, Figure 1B). As expected, heterozygous (*1/*28) and
homozygous variant (*28/*28) UGT1A1 carriers had increased
SN-38 plasma levels (Figure 1C). Interestingly, a significant
increase in SN-38 level was observed with an increasing number
of combined SLCO1B1 521C and UGT1A1*28 variant alleles,
suggesting an additive effect of polymorphisms in these two genes
(Figure 1D). A corresponding decrease in the SN-38G/SN-38 ratio
was observed with an increasing number of combined variant
alleles (Figure 1E). Together, this suggests that patients heterozygous for both SLCO1B1 521C and UGT1A1*28 may have an
equivalent risk of increased SN-38 exposure compared with
patients homozygous for either polymorphism, respectively.
Carriers of a rare SNP in CES1 (rs71647871, allele frequency,
0.024) had significantly decreased SN-38 levels (Po0.05, Table 3).
Interestingly, SN-38G levels were significantly affected by
ABCC5 genotype. Patients harbouring the ABCC5 rs562 C allele
had reduced SN-38G plasma exposure compared with wild-type
patients (P o0.001, Figure 1F, Supplementary Table 2). In
addition, patients expressing CYP3A5 also had significantly
reduced SN-38G plasma levels (P o0.05). FOLFIRI and FOLFIRINOX treatment regimens were significantly associated with
SN-38G (Po0.001 and P o0.05, respectively).

*1/*1

T/ C; C/C

*1/*28 *28/*28

UGT1A1*28

SLCO1B1 (521T>C)

***
**

15

*
SN-38G/SN-38 ratio

CSN-38 / dose / BSA
(10 –4 m2 ml–1)

4
3
2
1
0

**
10

5

0
0

1
2
3
Number of combined
variant alleles

20

**
CSN-38G / dose / BSA
(10 –4 m2 ml–1)

***

***
15
10
5
0

1
0
2
3
Number of combined
variant alleles

T/ T T/ C: C/C
ABCC5 rs562 T>C

Figure 1. Association between genotype and CPT-11 and metabolite plasma concentrations. (A) Effect of ABCB1 3435C4T genotype on dosenormalised CPT-11 plasma levels. Association between SLCO1B1 521T4C (B) and UGT1A1*28 (C) genotype and dose-normalised SN-38 levels.
Effect of increasing number of combined SLCO1B1 521C and UGT1A1*28 variant alleles on dose-normalised SN-38 plasma levels (D) and plasma
SN-38-G/SN-38 ratio (E). (F) Association between ABCC5 rs562 T4C genotype and SN-38-G plasma levels. *o0.05, **o0.01, ***o0.001.
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Table 3. Multiple linear regression model for effect on
Ln-transformed SN-38 concentration (adjusted R squared
0.2686), (n ¼ 127)

Table 4. Association between genotype and toxicity (n ¼ 127)

Predictor variable

Binary logistic regression (low vs high)b

Estimate

Standard error

P

 0.732

0.269

o0.01

0.160

0.104

0.124

 0.108

0.120

0.367

Other CPT-11 regimena

0.037

0.146

0.802

Male sex

0.092

0.079

0.250

Age

0.008

0.004

0.063

ABCB1 c.3435 (C/T)

0.015

0.096

0.872

ABCB1 c.3435 (T/T)

 0.202

0.112

0.074

SLCO1B1 c.521 (T/C;C/C)

0.269

0.080

0.001

UGT1A1 (*1/*28)

0.200

0.077

0.011

UGT1A1 (*28/*28)

0.456

0.137

0.001

 0.341

0.171

0.048

Intercept
FOLFIRI regimen
FOLFIRINOX regimen

CES1 rs71647871 (G/A)

Abbreviations: FOLFIRI ¼ 5-fluorouracil, irinotecan, leucovorin; FOLFIRINOX ¼ 5-fluorouracil, irinotecan, leucovorin, oxaliplatin.
a
Other CPT-11 regimen includes irinotecan as a single agent, irinotecan þ cetuximab, 5-FUirinotecan þ cetuximab.

The model for the inactive metabolite APC explained
approximately 24% of the variability in plasma exposure
(Supplementary Table 3). SLCO1B3 g.699 and ABCC2
c.1249G4A were positively associated with APC levels (Po0.01).
Decreased plasma levels were observed in patients carrying the
ABCC5 rs562 C allele compared with wild-type patients
(Po0.001). Significant adjusting covariates in this model included
sex (Po0.05) and treatment regimen (Po0.01).
Drug transporters predict CPT-11-related toxicities. CPT-11related adverse reactions and frequencies of grade severity are
described in Supplementary Table 4. Multinomial logistic regression analysis was performed to determine association of genotypes
to adverse reactions comparing no event vs low-grade vs highgrade toxicity (Table 4). ABCC2 -24C/T carriers had significantly
lower risk of grade 3/4 neutropenia compared with wild-type
patients (odds ratio (OR) ¼ 0.22, 95% CI ¼ 0.06–0.85). UGT1A1*28
carriers were at increased risk for severe neutropenia (grade 3/4)
compared with wild-type patients following binary logistic
regression analysing low- vs high-grade events (OR ¼ 3.67; 95%
CI ¼ 1.19–11.33; Table 4). In addition to their increased SN-38
exposure, patients with two or more combined SLCO1B1 521C and
UGT1A1*28 variant alleles were also at significantly increased risk
of severe neutropenia (grade 3/4) compared with patients wild-type
for both alleles (OR ¼ 4.154, 95% CI ¼ 1.06–16.36).
Non-haematological toxicity was associated with drug transporters and metabolising enzymes (Table 4). Carriers of a common
SNP in CES1 (rs2244613) had significantly lower risk of highergrade diarrhoea (OR ¼ 0.29, 95% CI ¼ 0.09–0.89). Patients with
ABCB1 3435 C/T and T/T genotypes were much more likely
to experience higher-grade nausea/vomiting (OR ¼ 9.06, 95%
CI ¼ 1.03–79.41 and OR ¼ 10.52, 95% CI ¼ 1.10–100.2, respectively). Higher-grade oral mucositis was observed in patients
expressing CYP3A5 (OR ¼ 8.10, 95% CI ¼ 1.57–41.90), whereas
those heterozygous for SLCO1B1 388A/G had a significantly lower
risk (OR ¼ 0.19, 95% CI ¼ 0.05–0.72). No significant adjusting
covariates were found in the binary logistic or multinomial logistic
regression models.
Biomarkers of PFS. Approximately 73% of patients were
considered responders having radiographic evidence of no change
or tumour shrinkage during CPT-11-based therapy. At the time of
www.bjcancer.com | DOI:10.1038/bjc.2015.5

Toxicity and
covariate
Neutropenia
UGT1A1*28 carriers

OR

3.67

95% CI

1.19—11.33

Multivariate Univariate
Pa
P

o0.05

o0.05
c

Multinomial logistic regression (no event vs low vs high)
Neutropenia
ABCC2–24 C/T
ABCC2–24 T/T

0.22
0.84

0.06—0.85
0.63—1.23

o0.05
0.85

0.07
0.08

Diarrhoea
CES1 rs2244613

0.29

0.09—0.89

o0.05

o0.05

Nausea/vomiting
ABCB1 3435 C/T
ABCB1 3435 T/T

9.06
10.52

1.03—79.41
1.10—100.2

0.06
o0.05

0.09
0.05

Oral mucositis
CYP3A5*3
SLCO1B1 388A/G
SLCO1B1 388G/G

8.1
0.19
0.62

1.57—41.90
0.05—0.72
0.13—2.99

o0.05
o0.05
0.55

o0.05
o0.05
0.74

Abbreviations: OR ¼ odds ratio; CI ¼ confidence interval.
a
Adjusted for age at enrolment, sex, and treatment regimen.
b
Low ¼ grades 0, 1, and 2; high grade ¼ grade 3 and 4.
c
Results are shown for no event vs high regression where high was considered as grade 3/4
(neutropenia) and grade 2/3 (diarrhoea, nausea/vomiting, and oral mucositis).

analysis (censor date: 13 August 2013), disease progression was
evident in the majority of patients with a median PFS time of
10.5 months (range, 0.2–43 months; Table 2). Cox-regression
analysis for PFS was performed on patients (excluding pancreatic
cancer patients) treated with BEV-FOLFIRI or FOLFIRI regimens
only (n ¼ 103, Table 5). Patients homozygous for SLCO1B1 388G/
G alleles had a significantly increased PFS compared with wild-type
patients (HR ¼ 1.60, 95% CI ¼ 1.04–2.46). Patients carrying two
ABCC2 c.-24T alleles had decreased PFS (HR ¼ 0.62, 95%
CI ¼ 0.40–0.95). Reduced PFS was also observed for UGT1A1*28
(*1/*28, HR ¼ 0.69, 95% CI ¼ 0.52–0.92; *28/*28, HR ¼ 0.60, 95%
CI ¼ 0.38–0.97). ABCC5 was associated with PFS in the univariate
analysis (P ¼ 0.05), but did not remain significant following
adjustment in the final model. No significant adjusting covariates
were found in the multivariate analysis.
Tumour OATP1B3 expression suggests poorer clinical
outcomes. The role of OATP1B3 expression, known to transport
SN-38, in response to CPT-11-based chemotherapy is unknown.
Recently, OATP1B3 expression within colon tumours has been
shown to be a cancer-specific isoform that may be expressed
primarily as an intracellular protein calling into question the
functional relevance of this transporter within the tumour
(Thakkar et al, 2013). Paired normal and tumour samples were
available for a subset of patients treated with CPT-11-based
chemotherapy regimens (n ¼ 30: BEV-FOLFIRI, n ¼ 22; FOLFIRI,
n ¼ 5; FOLFIRINOX, n ¼ 1; BEV-irinotecan, n ¼ 1; cetuximabirinotecan, n ¼ 1). Staining for OATP1B3 was performed and
intensity of expression was scored. Tumour tissue had a
significantly higher OATP1B3 score compared with paired normal
tissue (Po0.05, Figure 2A and C). Progression-free survival was
significantly reduced in patients with high (score, 2 or 3)
OATP1B3 expression compared with patients with low (score,
0 or 1) expression (Figure 2B), suggesting that OATP1B3 expression
may correlate with poorer clinical response to CPT-11 therapy.
DISCUSSION

Pharmacogenetics of irinotecan therapy has been widely studied
and UGT1A1*28 in particular, shown to be of potential clinical
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Table 5. Association of genotypes and progression-free survival (n ¼ 103)
Genotype

No. of patients

SLCO1B1*1b (388 A4G)
A/A

35

HR

95% CI

1.27

1.05—1.54

MultivariatePa

o0.05

1.00

A/G

52

1.02

0.76—1.37

0.92

G/G

16

1.60

1.04—2.46

o0.05

0.84

0.68—1.03

ABCC2 (-24 C4T)
C/C

Univariate P

60

0.09

1.00

C/T

33

0.99

0.73—1.35

0.97

T/T

10

0.62

0.40—0.95

o0.05

0.75

0.62—0.93

UGT1A1*28

o0.01

6/6

46

1.00

6/7

49

0.69

0.52—0.92

o0.05

7/7

8

0.60

0.38—0.97

o0.05

0.81

0.66—1.00

ABCC5 (rs562 T4C)

0.05

Abbreviations: HR ¼ hazard ratio; CI ¼ confidence interval. Bold entries are to signify their statistical significance.
a
Adjusted for age at enrolment, sex, and treatment regimen (FOLFIRI).
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Figure 2. Effect of OATP1B3 tumour expression on progression-free
survival in patients treated with CPT-11-based chemotherapy
regimen. (A) Pathology score of OATP1B3 expression in paired
samples of normal, normal adjacent, and tumour tissue (n ¼ 30).
(B) Association between OATP1B3 tumour score and progression-free
survival in patients. (C) Representative immunohistochemistry of
OATP1B3 expression in normal and tumour colon tissue. *o0.05.

relevance especially for patients prescribed high-dose CPT-11
therapy (Hoskins et al, 2007). As severe toxicities are often
observed in patients treated with combination regimens at lower
CPT-11 doses, we examined pharmacogenetic determinants of
CPT-11 and metabolite exposure in this setting.
862

CPT-11
SN-38

CE

D

S1

UGT1A1

SN-38G

Diarrhoea

Intestinal
-glucoronidases

Figure 3. Schematic model depicting known and new insight into the
metabolism and transport of CPT-11, SN-38, and SN-38G and the
proposed effect on treatment-related toxicities and response.
Increased SN-38 exposure due to combined SLCO1B1 and UGT1A1
variants correlates with an increased risk for neutropenia. Increased
intestinal SN-38G, due to reduced ABCC5 hepatic efflux, may lead to
increased risk for diarrhoea as SN-38G is converted to SN-38 via
intestinal b-glucoronidases. Circles with check marks indicate an effect
on neutropenia (N), diarrhea (D), and progression-free survival (P).

SN-38 plasma exposure was significantly increased SLCO1B1
521C (*5) allele carriers (Po0.001) (Figure 3) consistent with
studies correlating SLCO1B1 521C to higher SN-38 and CPT-11
AUC in both colorectal cancer and non-small-lung cell cancer
patients (Han et al, 2008; Innocenti et al, 2009). UGT1A1*28
carriers had significantly increased SN-38 levels compared with
non-carriers (Po0.01) consistent with previous reports, which can
result in greater toxicity risk (Iyer et al, 2002; Innocenti et al, 2009;
Hu et al, 2010; Sai et al, 2010; Cai et al, 2013). Importantly, we
demonstrate an additive effect of SLCO1B1 521C and UGT1A1*28
on SN-38 exposure as patients with an increasing number of
combined variant alleles had higher plasma levels and a
corresponding decrease in the SN-38G/SN-38 ratio. To our
www.bjcancer.com | DOI:10.1038/bjc.2015.5

OATP1B transporters as biomarkers for irinotecan therapy

knowledge this is the first report of an additive effect in a primarily
Caucasian (94%) population, which remained significant upon
exclusion of non-Caucasian patients. A similar additive effect has
been noted for SN-38 AUC with combined SLCO1B1*15 and
UGT1A1*6 or *28 polymorphisms in Japanese patients, likely due
to the presence of the SLCO1B1 521C allele (Sai et al, 2010).
Together, these results suggest that heterozygous carriers of both
SLCO1B1 521C and UGT1A1*28 may reach a toxicity risk
comparable to homozygous UGT1A1*28 patients as evidenced by
several case reports of SLCO521C and UGT1A1*28 carriers
presenting with life-threatening toxicities (Sakaguchi et al, 2009;
Takane et al, 2009). Here we observed an OR of 4.15
(95%CI ¼ 1.06–16.36) for grade 3/4 neutropenia in patients with
two or more combined variant allele. The clinical relevance of the
additive effect of these two genes may be underestimated and need
to be further examined as a better strategy for personalising CPT11 therapy.
Although plasma SN-38 levels appear to be the most predictive
of toxicity risk, secondary metabolites, SN-38G and APC, may also
be important contributors. We observed decreased plasma levels of
these metabolites associated with an ABCC5 polymorphism (rs562)
that was recently identified as a significant predictor of GI toxicity
(Di Martino et al, 2011). These effects may be due to reduced
ABCC5 hepatic efflux leading to SN-38G and APC accumulation
within the liver (Figure 3). Higher hepatic concentrations may
ultimately lead to increased intestinal SN-38G levels, through
increased biliary excretion via other ABC transporters, which may
then undergo b-glucuronidase-dependent reconversion to SN-38
thereby augmenting GI toxicity risk (Figure 3).
In this study, CPT-11 levels were lower in homozygous ABCB1
3435T patients. ABCB1 is a well-established transporter of CPT-11
and SN-38, but its clinical relevance for CPT-11 therapy remains
inconclusive. ABCB1 polymorphisms have been associated with
both increased or reduced exposure, decreased clearance and
increased toxicity and response, whereas other studies were unable
to confirm these results (Mathijssen et al, 2003; Sai et al, 2003;
Mathijssen et al, 2004; Cote et al, 2007; Innocenti et al, 2009; Sai
et al, 2010; Glimelius et al, 2011). This may be due to the
redundancy of other transporters, including ABCC2 and ABCG2,
capable of biliary excretion of CPT-11 and metabolites. The lack of
consistent evidence suggests that ABCB1 may not be useful in
personalising CPT-11 therapy.
As a secondary objective we examined the impact of
pharmacogenetic factors on adverse events and PFS. Here, the
majority (97%) of patients were prescribed 180 mg m  2 CPT-11
with 17% experiencing severe neutropenia. Neutropenia was
associated with UGT1A1*28 as has been reported (Hoskins et al,
2007). More importantly, patients carrying two or more combined
SLCO1B1 521C and UGT1A1*28 alleles were at significantly
increased risk of myelosuppression, suggesting these SNPs together
may provide a more comprehensive strategy for assessing
haematological toxicity risk. Heterozygous ABCC2–24C/T but not
TT carriers predicted reduced neutropenia risk indicating further
validation is needed.
Non-haematological toxicities including diarrhoea, nausea/
vomiting, and oral mucositis were assessed. Most notably, a
common SNP in CES1 (rs2244613) was associated with lower risk
of diarrhoea, which may be due to reduced conversion of CPT-11
to SN-38. CES1 (rs2244613) was recently associated with reduced
trough levels of dabigatran, a new oral anticoagulant drug, and a
significantly decreased bleeding risk in patients, suggesting this
SNP may be clinically relevant for many CES-dependent drugs
(Pare et al, 2013). Interestingly, homozygous ABCB1 3435T carriers
had a much higher likelihood of experiencing higher-grade nausea/
vomiting (OR ¼ 10.52, Po0.05) and patients expressing CYP3A5
had a significantly increased risk of oral mucositis, suggesting
higher levels of M4, APC, or NPC metabolites may contribute its
www.bjcancer.com | DOI:10.1038/bjc.2015.5
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development. A potential limitation to this analysis is the
concurrent use of 5-fluorouracil with CPT-11 in most patients.
Although the side-effect profile of the two drugs is similar, the
majority of markers assessed are not specific to 5-fluorouracil,
suggesting these correlations are likely due to modulation of
irinotecan disposition but require confirmation in a study designed
to assess toxicity as a primary objective.
PFS analysis was limited to patients treated with FOLFIRI with
or without BEV. SLCO1B1 388(G/G) was associated with longer
PFS, suggesting variant carriers may experience better response to
FOLFIRI-based regimens. This effect may be due to increased
OATP1B1 expression as this variant has recently been correlated to
increased expression in Caucasian liver samples (Nies et al, 2013).
ABCC2–24TT was associated with reduced PFS, consistent with
lower response rates and shorter PFS observed in Japanese patients,
but contrary to the lack of association in Caucasian metastatic
colorectal cancer patients treated with FOLFIRI regimes (Akiyama
et al, 2012). UGT1A1*28 was also associated with reduced PFS, but
a recent meta-analysis suggested that UGT1A1*28 status may not
be a reliable predictor of PFS (Liu et al, 2013). Our evaluation of
PFS may be confounded by patients still undergoing active therapy
or surveillance at the date of censoring. Although the genes
investigated are not thought to have a role in the other drugs in the
FOLFIRI regimen, we cannot rule out the effect of these drugs
on PFS.
Importantly, we analysed OATP1B3 tumour expression in a
subset of patients. To date, tumour biomarkers of CPT-11 response
remain unknown. Our group was the first to note OATP1B3
overexpression in colon tumours and this expression was recently
identified exclusively as a cancer-specific (cs)OATP1B3 splice
variant (Lee et al, 2008; Han et al, 2013; Imai et al, 2013; Thakkar
et al, 2013). The localisation (thought to be intracellular), function,
and clinical relevance of csOATP1B3 are under investigation (Imai
et al, 2013; Thakkar et al, 2013). Here we show the first evidence, to
our knowledge, that higher OATP1B3 expression in colon tumours
was significantly associated with reduced PFS (Figure 3). Lack of
membrane expression of a functional OATP1B3 transporter may
lead to reduced SN-38 tumour influx leading to a poorer clinical
response or alternatively, overexpression of csOATP1B3 within the
tumour may induce a p53-dependent survival mechanism, which
has been demonstrated in WT-OATP1B3 colon cancer cell lines
(Lee et al, 2008). Although we are unable to definitively confirm
OATP1B3 to be the cancer-specific isoform due to use of an
antibody recognising the common c-terminal region, the reported
lack of wild-type OATP1B3 expression within colon tumours
suggests this is the form expressed in these tumours (Thakkar et al,
2013).
Owing to the complexity of CPT-11 disposition, it is questionable that one gene alone will be useful for personalising therapy
and will likely require assessing the right combination of genes.
Our data provide new insight regarding transporters, particularly
members of the OATP1B subfamily, to the disposition and clinical
effects of CPT-11 (summarised in Figure 3). The additive effect of
SLCO1B1 521C and UGT1A1*28 on SN-38 exposure and
neutropenia risk seen here in patients carrying two or more
combined alleles (24.8% of this population) provides rationale for
examining the utility of combined genotyping to better predict
toxicity risk in CPT-11-based regimens. Future prospective studies
should be designed to compare combined genotyping to
UGT1A1*28 genotyping alone to advance the goal of personalising
irinotecan.
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